Microsphere embolism (ME)-induced
cerebral ischemia can elicit various pathological events leading to neuronal death. Western blotting and immunohistochemical studies revealed that expression of
calpastatin, an endogenous
calpain inhibitor, decreased after ME induction.
Calpain activation after ME was apparently due to, in part, a decrease in
calpastatin in a late phase of neuronal injury. The time course of that decrease also paralleled
caspase-3 activation. In vitro studies demonstrated that
calpastatin was degraded by
caspase-3 in a Ca(2+)/
calmodulin (CaM)-dependent manner. Because CaM binds directly to
calpastatin, we asked whether a novel CaM antagonist, 3-[2-[4-(3-chloro-2-methylphenylmethyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-
indazole dihydro-
chloride 3.5 hydrate (DY-9760e), inhibits caspase-3-induced
calpastatin degradation during ME-induced neuronal damage. We also tested the effect of
DY-9760e on degradation of
fodrin, a
calpain substrate. Consistent with our hypothesis,
DY-9760e (25 or 50 mg/kg i.p.) treatment inhibited degradation of
calpastatin and
fodrin in a dose-dependent manner. Because
DY-9760e showed powerful neuroprotective activity with concomitant inhibition of
calpastatin degradation, cross-talk between
calpain and
caspase-3 through
calpastatin possibly accounts for ME-induced neuronal injury. Taken together, both inhibition of caspase-3-induced
calpastatin degradation and
calpain-induced
fodrin breakdown by
DY-9760e in part mediate its neuroprotective action.